IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma
Primary Purpose
Glioma
Status
Unknown status
Phase
Early Phase 1
Locations
China
Study Type
Interventional
Intervention
68Ga-BBN-IRDye800CW
Sponsored by
About this trial
This is an interventional diagnostic trial for Glioma
Eligibility Criteria
Inclusion Criteria:
- Must be able to provide a written informed consent
- suspected lower grade gliomas on contrast-enhanced MRI
Exclusion Criteria:
- Consisted of conditions of mental illness
- Severe liver or kidney disease with serum creatinine > 3.0 mg/dl (270 μΜ)
- Any hepatic enzyme level 5 times or more than normal upper limit
- Severe allergy or hypersensitivity to IV radiographic contrast
- Claustrophobia to accept the PET/CT or PET/MRI scanning
- Pregnancy or breast feeding
Sites / Locations
- Beijing Tiantan HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
68Ga-BBN-IRDye800CW PET/NIRF
Arm Description
The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
Outcomes
Primary Outcome Measures
Standardized uptake value of 68Ga-BBN-IRDye800CW in PET imaging of lower grade gliomas
The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in lower grade glioma will be measured.
Secondary Outcome Measures
The sensitivity and specificity of intraoperative IRDye800CW-BBN fluorescence
The sensitivity and specificity of intraoperative IRDye800CW-BBN fluorescence, and the preoperative PET and MRI imaging indicator for IRDye800CW-BBN fluorescence imaging in lower grade gliomas
Full Information
NCT ID
NCT03407781
First Posted
January 16, 2018
Last Updated
January 16, 2018
Sponsor
Deling Li
Collaborators
Peking Union Medical College Hospital, National Institute for Biomedical Imaging and Bioengineering (NIBIB), Chinese Academy of Sciences
1. Study Identification
Unique Protocol Identification Number
NCT03407781
Brief Title
IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma
Official Title
IRDye800CW-BBN PET-NIRF in Lower Grade Glioma
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2016 (Actual)
Primary Completion Date
December 30, 2018 (Anticipated)
Study Completion Date
December 30, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Deling Li
Collaborators
Peking Union Medical College Hospital, National Institute for Biomedical Imaging and Bioengineering (NIBIB), Chinese Academy of Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is an open-label positron emission tomography/near infrared (PET/NIRF) study to investigate the imaging navigation performance and evaluation efficacy of dual modality imaging probe 68Ga-BBN-IRDye800CW in patients with lower grade glioma. A single dose of 40μg/111-148 Mega-Becquerel (MBq) 68Ga-NOTA-BBN and 1.0- or 2.0- mg/ml IRDye800CW-BBN will be injected intravenously before the operation and intraoperative respectively. Visual and semiquantitative method will be used to assess the PET images and real-time margins localization for surgical navigation.
Detailed Description
Lower grade gliomas (WHO grades II and III) are currently diffused disease with variability of tumor behaviors and of challenge to distinguish the margins in white-light microscope during the surgery. An integrated dual-modality approach combining preoperative positron emission tomography imaging with intraoperative optical guidance that target the same tumor biomarker would be of grade help to solve this problem. BBN, with the amino acid sequence of Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, has been extensively used for the development of molecular probes for the imaging of gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptor family of bombesin receptors that over-expressed in various types of cancer cells including glioma. For interests in clinical translation of GRPR targeting dual modality probe, an open label dual modality imaging PET/ NIFR study was designed to investigate the imaging guiding performance in lower grade glioma patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioma
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
68Ga-BBN-IRDye800CW PET/NIRF
Arm Type
Experimental
Arm Description
The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
Intervention Type
Drug
Intervention Name(s)
68Ga-BBN-IRDye800CW
Other Intervention Name(s)
IRDye800CW-BBN
Intervention Description
PET/NIR fluorescent imaging-guided surgery
Primary Outcome Measure Information:
Title
Standardized uptake value of 68Ga-BBN-IRDye800CW in PET imaging of lower grade gliomas
Description
The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in lower grade glioma will be measured.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
The sensitivity and specificity of intraoperative IRDye800CW-BBN fluorescence
Description
The sensitivity and specificity of intraoperative IRDye800CW-BBN fluorescence, and the preoperative PET and MRI imaging indicator for IRDye800CW-BBN fluorescence imaging in lower grade gliomas
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Must be able to provide a written informed consent
suspected lower grade gliomas on contrast-enhanced MRI
Exclusion Criteria:
Consisted of conditions of mental illness
Severe liver or kidney disease with serum creatinine > 3.0 mg/dl (270 μΜ)
Any hepatic enzyme level 5 times or more than normal upper limit
Severe allergy or hypersensitivity to IV radiographic contrast
Claustrophobia to accept the PET/CT or PET/MRI scanning
Pregnancy or breast feeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Deling Li, MD
Email
ttyyneuroli@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jingjing Zhang, MD.PhD.
Email
zhangjingjingtag@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhaohui Zhu, MD
Organizational Affiliation
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Nan Ji, MD
Organizational Affiliation
Beijing Tiantan Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Beijing Tiantan Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Deling Li, MD
12. IPD Sharing Statement
Learn more about this trial
IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma
We'll reach out to this number within 24 hrs